19 marzo 2015
Orthopedic surgeons have conducted a cost-benefit analysis of topical tranexamic acid in primary total hip and knee arthroplasty patients that revealed a 12 percent transfusion rate reduction — from 17.5 percent to 5.5 percent — with no significant difference in complication rates.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/wr0ztyyUGLU/150319113015.htm
